Galaxy Therapeutics – Trademark Portfolio

Entity Type: 03

Galaxy Therapeutics holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 6 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include SEAL XL, SEAL ARC, SEAL BASE, and SACCULAR ENDOVASCULAR ANEURYSM LATTICE (SEAL). The owner is based in Malpitas, CA.

799 Ames

Malpitas, CA 95131

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Galaxy Therapeutics's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (6 filings)

Surgical, medical, dental and veterinary apparatus and instruments

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Galaxy Therapeutics have?

Galaxy Therapeutics has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 abandoned.

What trademark classes does Galaxy Therapeutics file in?

Galaxy Therapeutics files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 1 (Chemicals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Galaxy Therapeutics's most well-known trademarks?

Galaxy Therapeutics's registered trademark portfolio includes well-known marks such as SEAL XL, SEAL ARC, SEAL BASE, and SACCULAR ENDOVASCULAR ANEURYSM LATTICE (SEAL). These are among 4 currently registered trademarks in the portfolio.

What is Galaxy Therapeutics's trademark registration success rate?

Galaxy Therapeutics has a 57% trademark registration rate, with 4 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.